Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

600276

株式のランク #544
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
株価
$6.89
時価総額
$43.94B
変化(1日)
-2.91%
変化(1年)
-24.78%
国
CN
取引 Jiangsu Hengrui Medicine Co., Ltd. (600276)

カテゴリー

Healthcare
Jiangsu Hengrui Medicine Co., Ltd.(600276)のP/S比率
October 2026 時点のP/S比率 TTM: 9.37
Jiangsu Hengrui Medicine Co., Ltd. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 9.37 です。2024 年末時点でのP/S比率は 10.39 でした。
Jiangsu Hengrui Medicine Co., Ltd. の P/S 比率の履歴(2001 ~ 2026)
各年末時点のP/S比率
年 P/S比率 変化
2026 (TTM) 9.37 -23.96%
2025 12.32 18.54%
2024 10.39 -17.13%
2023 12.54 8.76%
2022 11.53 -7.68%
2021 12.49 -41.32%
2020 21.29 28.72%
2019 16.54 47.69%
2018 11.20 -3.36%
2017 11.59 44.55%
2016 8.02 -6.62%
2015 8.58 63.97%
2014 5.24 -9.71%
2013 5.80 21.57%
2012 4.77 -5.76%
2011 5.06 -38.70%
2010 8.26 10.18%
2009 7.49 29.72%
2008 5.78 -34.42%
2007 8.81 78.87%
2006 4.92 420.22%
2005 0.95 14.31%
2004 0.83 -8.27%
2003 0.90 -28.02%
2002 1.25 -16.11%
2001 1.50 0.00%
同業他社のP/S比率